To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients



Status:Completed
Conditions:Migraine Headaches
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 45
Updated:12/29/2017
Start Date:November 11, 2015
End Date:November 8, 2017

Use our guide to learn which trials are right for you!

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to
Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced
Migraine-like Attacks in Migraine Patients.


Inclusion Criteria:

- Adults ≥ 18 to ≤ 45 years of age upon entry into screening

- History of migraine headaches without aura for ≥ 6 months prior to screening according
to the IHS Classification ICHD-II (Headache Classification Committee of the
International Headache Society, 2004) based on medical records and/or patient
self-report

- Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior
to screening

Exclusion Criteria:

- History of migraine with aura, cluster headache or hemiplegic migraine headache
according to the IHS Classification ICHD-II (Headache Classification Committee of the
International Headache Society, 2004) based on medical records and/or patient
self-report

- ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during
screening period

- Other headache disorders (except for episodic tension-type headache <5 days/month)
We found this trial at
2
sites
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
?
mi
from
Leuven,
Click here to add this to my saved trials